CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
People›
Anna Wagner
AddedSep 27, 2026
UpdatedSep 27, 2026
Anna Wagner

Anna Wagner

CEO and Co-Founder, Transfyr

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Anna Wagner's Career

Transfyr

Transfyr

Seed$25MCambridge, MA, US
CEO and Co-Founder

Recent news

Physical AI: Transfyr Launches Platform for ScienceEl Solitario · 2026
Transfyr Launches With $25M to Fix Science's Data GapPomegra · 2026
Transfyr Raises $25M to Build AI Infrastructure for ScienceGeneration Hope · 2026

Leadership at Transfyr

Renee WegrzynRenee WegrzynCo-Founder & Chief Innovation Officer

Similar to Transfyr

Lila SciencesLila SciencesCambridge, MA, USest. 2023Lila SciencesCambridge, MA, US · est. 2023

Lila builds scientific superintelligence software and autonomous laboratories for AI-driven research and experimentation.

Series A · $550M449
Aether AIAether AISan Diego, CA, USest. 2026Aether AISan Diego, CA, US · est. 2026

Aether AI builds causal world models for Physical AI and robotics.

Seed · $20M
FluidizeFluidizeSan Francisco, CA, USest. 2025FluidizeSan Francisco, CA, US · est. 2025

Fluidize is an AI platform that accelerates scientific R&D by automating simulation and experiment workflows for scientists and engineers.

Seed · $500k3
MithrlMithrlSan Francisco, CA, USest. 2023MithrlSan Francisco, CA, US · est. 2023

Mithrl builds AI infrastructure and biomedical world models for biopharma R&D teams.

Series A · $24M24
Ginkgo Bioworks

Ginkgo Bioworks

Public$1.6BBoston, MA, US
Head of AI

Recent news

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous LabPR Newswire · 2026
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of Its Non-Core Biosecurity BusinessPR Newswire · 2026
NeuImmune and Ginkgo Bioworks Launch Strategic Collaboration to Accelerate Precision BiologicsNeuImmune · 2025

Leadership at Ginkgo Bioworks

Reshma ShettyReshma ShettyPresident
Austin CheAustin CheHead of Strategy
Barry CantonBarry CantonChief Technology Officer
Shyam SankarShyam SankarChairman
Harry Evans SloanHarry Evans SloanBoard Member
Tom KnightTom KnightFounder

Similar to Ginkgo Bioworks

Prolific MachinesProlific MachinesEmeryville, CA, USCell Manufacturingest. 2020Prolific MachinesEmeryville, CA, US · est. 2020

Prolific Machines develops a light-controlled platform that programs living cells to manufacture therapeutic proteins and other bioproducts.

Series C · $147M67
StrateosStrateosMenlo Park, CA, USLab Automation, Researchest. 2019StrateosMenlo Park, CA, US · est. 2019

Strateos: A data-driven life science company advancing research efficiency through automation and robotics.

Series B · $105.8M83
CodexisCodexisRedwood City, CA, USEnzyme Developmentest. 2002CodexisRedwood City, CA, US · est. 2002

Protein engineering company delivering enzymatic solutions for RNA and pharma manufacturing.

Public · $162M248
BenchlingBenchlingSan Francisco, CA, USRD Platform, Softwareest. 2012BenchlingSan Francisco, CA, US · est. 2012

Benchling develops cloud software for biotechnology R&D, connecting scientific data, experiments, workflows, and research teams.

Series F · $411.9M808

People Similar to Anna Wagner

Richard W SchwartzRichard W SchwartzBoard Member · Ginkgo BioworksJason KellyJason KellyFounder · Ginkgo BioworksMax HodakMax HodakFounder & CEO · TranscripticKenny WorkmanKenny WorkmanCo-Founder · LatchBioChristian HenryChristian HenryPresident and Chief Executive Officer · Pacific Biosciences of California